Vigonvita Life Sciences Co., Ltd. (HKG:2630)

Hong Kong · Delayed Price · Currency is HKD

86.45

+3.60 (4.35%)

Aug 20, 2026, 4:09 PM HKT

-9.00% (1Y)

Market Cap	14.49B
Revenue (ttm)	113.61M +762.9%
Net Income	-395.85M
EPS	-2.59
Shares Out	167.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92,600
Open	82.00
Previous Close	82.85
Day's Range	82.00 - 89.35
52-Week Range	51.00 - 134.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Vigonvita Life Sciences

Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116,... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 2013

Country China

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2630

Full Company Profile

Financial Performance

In 2025, Vigonvita Life Sciences's revenue was 102.10 million, an increase of 762.88% compared to the previous year's 11.83 million. Losses were -355.72 million, 68.3% more than in 2024.

Financial numbers in CNY Financial Statements